Lysine kinetics in preterm infants: the importance of enteral feeding

S R D van der Schoor1, P J Reeds, F Stellaard

  • 1Erasmus MC-Sophia Children's Hospital, Department of Paediatrics, Dr Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands.

Gut
|December 20, 2003
PubMed

Insights

First pass lysine metabolism in preterm infants is higher with partial enteral feeding. Full enteral feeding improves lysine balance and protein deposition compared to parenteral administration.

Area of Science:

  • Biochemistry
  • Neonatal Nutrition
  • Pediatric Gastroenterology

Background:

  • Lysine is an essential amino acid crucial for newborn development.
  • Intestinal first-pass metabolism significantly impacts systemic lysine availability.
  • Understanding lysine metabolism in preterm infants is vital, especially with varying enteral intake levels.

Purpose of the Study:

  • To investigate the extent of intestinal first-pass lysine metabolism in preterm infants.
  • To compare lysine kinetics under partial versus full enteral feeding conditions.
  • To determine the impact of feeding method on lysine utilization and balance in preterm neonates.

Main Methods:

  • Study involved six preterm infants with low birth weight.
  • Dual stable isotope tracer techniques were employed to measure lysine kinetics.
  • Infants were assessed during two feeding periods: 40% enteral/60% parenteral and 100% enteral feeding.

Main Results:

  • Fractional intestinal lysine uptake was significantly higher during partial enteral feeding (32% vs. 18%).
  • Absolute lysine uptake did not differ significantly between feeding groups.
  • Whole body lysine oxidation decreased, and lysine balance improved with full enteral feeding.

Conclusions:

  • Preterm infants exhibit higher fractional intestinal lysine uptake during partial enteral feeding.
  • Full enteral feeding enhances lysine utilization, reducing oxidation and improving net balance.
  • Dietary lysine is more effective than parenteral lysine in promoting protein deposition in preterm infants.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
2.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
982
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
562
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
417
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
414